Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

CHADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that by mutual agreement it has concluded its research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza's Staccato(R) inhalation technology. The product, Staccato(R) fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003 in North America.

Ivan Gergel, M.D., Endo's executive vice president of research and development, stated: "As a result of our ongoing strategic review initiated last year, we have terminated certain research and development programs. We have enjoyed working with Alexza and wish them success with their drug development programs. In the meantime, we remain committed to building our pipeline by pursuing programs at all phases of development, including potential products arising from our virtual discovery program."

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain i
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
(Date:3/31/2015)... MALVERN, Pa. , March 31, 2015  SCILEX ... commercialization of products focused on the treatment of pain, ... Tokyo Japan ), a member of ITOCHU ... one of the three leading sogo shosha (general trading ... a strategic investment in SCILEX.  ICF has worked closely ...
(Date:3/31/2015)... 31, 2015 Medela has announced the ... Invia ® Motion™-Endure personal pumps to its Negative ... services. These new devices, along with the Invia ... to provide innovative, high-quality NPWT solutions, designed to ... patients. "We are happy to be ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2
... Calif., May 3, 2012 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Complete Response Letter (CRL) from the U.S. Food and Drug ... (loxapine) inhalation powder, 5 mg and 10 mg.  The CRL ... indicating that the NDA review cycle is complete and the ...
... BELGRADE, Mont., May 3, 2012  Bacterin International Holdings, Inc. (NYSE ... of revolutionary bone graft material and antimicrobial coatings for medical ... ended March 31, 2012:  2012 Highlights: ... the $6.0 million for the first quarter of 2011. ...
Cached Medicine Technology:Alexza Receives Complete Response Letter for Adasuve™ NDA 2Alexza Receives Complete Response Letter for Adasuve™ NDA 3Alexza Receives Complete Response Letter for Adasuve™ NDA 4Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 2Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 3Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 4Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 5Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 6Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 7Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 8Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 9Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss 10
(Date:3/31/2015)... BESLER Consulting today announced the ... of an Independent Cost Report Review.” , The ... role in the determination of Medicare reimbursement to ... and review, this report can assist management in ... This white paper discusses:,     The ...
(Date:3/31/2015)... March 31, 2015 Greenfield Senior ... Investment Trust LLC ("Care") a seniors housing-focused real ... Inc. Care announces today, their acquisition of six ... for $54.48 million. Concurrent with the acquisition, Care ... Greenfield Senior Living ("Greenfield"). Pursuant to the lease, ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Nutrition ... the presentation of new clinical study results supporting ... silicate (ASI), titled, “Arginine Silicate Supplementation Decreases Markers ... Markers of Vasodilation and Cardiovascular Health in Healthy ... and other professionals at the acclaimed Experimental Biology ...
(Date:3/31/2015)... 31, 2015 More than 120 of ... to express their shared support for the same basic ... a 'True Health Coalition' and a lifestyle medicine initiative ... help demonstrate that, despite appearances to the contrary, there ... about the theme of healthful eating and living. ...
(Date:3/31/2015)... 31, 2015 As the scientific community ... Balance Network (GEBN) is poised to make meaningful ... health. GEBN is a network of scientists from ... Asia and Oceania who have banded together to further ... the body (energy balance) and apply this understanding to ...
Breaking Medicine News(10 mins):Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 3Health News:Nutrition 21, LLC Announces the Presentation of Proteomic Results of a Nitrosigine® Clinical Study at the Renowned Experimental Biology 2015 Annual Meeting 2Health News:Nutrition 21, LLC Announces the Presentation of Proteomic Results of a Nitrosigine® Clinical Study at the Renowned Experimental Biology 2015 Annual Meeting 3Health News:Nutrition 21, LLC Announces the Presentation of Proteomic Results of a Nitrosigine® Clinical Study at the Renowned Experimental Biology 2015 Annual Meeting 4Health News:Nutrition 21, LLC Announces the Presentation of Proteomic Results of a Nitrosigine® Clinical Study at the Renowned Experimental Biology 2015 Annual Meeting 5Health News:Nutrition 21, LLC Announces the Presentation of Proteomic Results of a Nitrosigine® Clinical Study at the Renowned Experimental Biology 2015 Annual Meeting 6Health News:GLiMMER Initiative Founder David Katz, MD Announces the Launch of the True Health Coalition: Worldwide Experts Convened to Defend Fundamentals of Healthy Eating/Living 2Health News:GLiMMER Initiative Founder David Katz, MD Announces the Launch of the True Health Coalition: Worldwide Experts Convened to Defend Fundamentals of Healthy Eating/Living 3Health News:GLiMMER Initiative Founder David Katz, MD Announces the Launch of the True Health Coalition: Worldwide Experts Convened to Defend Fundamentals of Healthy Eating/Living 4Health News:Global Energy Balance Network Experts from Six Continents Join Forces to Reduce Obesity, Including the University of Colorado Anschutz Health and Wellness Center's James O. Hill, PhD 2Health News:Global Energy Balance Network Experts from Six Continents Join Forces to Reduce Obesity, Including the University of Colorado Anschutz Health and Wellness Center's James O. Hill, PhD 3
... grant from the American Cancer Society, Yanchang Wang, assistant professor ... Medicine, hopes to learn how a particular enzyme could possibly ... that occurs in many forms of cancer. , Wangs research ... deactivating the cell division process set in motion by another ...
... DHR ) announced that President and Chief Executive ... the Citigroup Global Industrial,Manufacturing Conference in New York ... The audio will be simultaneously webcast on, http://www.danaher.com ... for one week., Danaher Corporation is ...
... is a worry, study says, , , MONDAY, Feb. 25 (HealthDay ... dementia are given antibiotics in the last two weeks of ... whether or not that therapy has any benefits, such as ... of concern are the risks associated with antibiotic use, such ...
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... doubles US Phase I capacity, RALEIGH, N.C., Feb. ... announced the grand opening of its,expanded, newly built Clinical ... occasion with a special event at the facility on,Wednesday, ... Center,s size to 80,beds, with the clinic occupying the ...
... DONATES $250,000 TO THE LARRY KING CARDIAC FOUNDATION AS PART OF ... SMART HEART ... beat when,partnering with Larry King to help save hearts. Thanks to ... Challenge, Quaker(R),Oatmeal is donating $250,000 to the Larry King Cardiac Foundation ...
Cached Medicine News:Health News:FSU College of Medicine researcher seeks to uncover new cancer therapies 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
... 4 shelves. Over-sized compressor. Triple ... interior lighting. Self-Contained System No plumbing required. ... Full One Year Warranty on Parts & Labor ... Also available as a chromatography unit ...
Inquire...
... Series refrigerators from Taylor-Wharton are uniquely designed ... convenient box-type storage racks and the lower ... storage. The RackSystems are available in four ... from 750 x 2ml vials to 4800 ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
Medicine Products: